Efficacy of AIDS Drugs Ebbing

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Efficacy of AIDS Drugs Ebbing

Boston Globe (12.19.01) - Thursday, December 20, 2001
Raja Mishra

"We could be right back where we were in 1984, when the virus was unstoppable," said Larry Kessler, executive director of Boston's AIDS Action Committee, of the news that the vast majority of US HIV patients carry a form of the disease able to resist one or more HIV drugs. The study, released this week at the American Society of Microbiology conference in Chicago, reported that 78 percent of the patients tracked developed resistance to at least one of the 15 AIDS drugs available.

"This is something that we really have been worrying about, dreading," Kessler said. He had assumed, based on smaller previous studies, that one in four HIV cases were resistant rather than three in four, as the new study indicates. The study suggests that a new generation of patients might not have the luxury of trying different drug combinations, and that older patients, who have cycled through many medications, are running out of time.

"If I should happen to fail the cocktail I'm taking, I don't know where to go," said Charles Lacombe, 53, of Boston, whose HIV is resistant to most AIDS drugs. Diagnosed with HIV in 1992, Lacombe began taking three AIDS drugs, including the protease inhibitor crixivan and AZT in 1995. But the side effects - pancreas damage, kidney stones and fatty deposits - were so severe that his doctor put him on new drugs. Almost immediately after the first drug combination was cut off, his HIV became resistant to all protease inhibitors, AZT and a third class of drugs. His current regimen might be the last effective combination, he said. But many of the gay men he socializes with continue to believe AIDS drugs offer lifetime protection. "People are back to the same old practices that started this epidemic anyway," Lacombe said.

Dr. Ronald Valdiserri, deputy chief of STDs at the CDC, had similar concerns and said the new study "underscores the importance of prevention" of new infections.
011220
AD012209

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.